

# Sun Pharmaceutical Industries Ltd


## Q4FY11 Result Summary

Rs mn	Q4FY11	Q3FY11	Q4FY10	q-o-q (%)	y-o-y (%)
Net Sales	14633	16011	11092	-9	32
Other Income	1108	258	-111	330	1094
Raw Material Cost	3132	4324	2662	-28	18
Employees cost	2540	2754	1160	-8	119
Other expenses	4525	4528	3085	0	47
EBITDA	5544	4663	4074	19	36
EBITDA margin	38	29	37	880bps	120bps
Depreciation	482	805	419	-40	15
EBIT	5062	3859	3654	31	39
Interest and finance charges	0	-322	-249	100	100
PBT	5062	4181	3903	21	30
Tax	22	545	-13	-96	278
PAT	5039	3636	3916	39	29
PAT Margin (%)	34	23	35	1170bps	-90bps
No of equity shares (Mn)	1035.6	1035.6	207.1		
EPS (Rs)	4.3	3.4	19	26.5	-77.4


Top line increased by 32% on y-o-y basis in Q4FY11, largely on account of growth in sales of branded prescription formulation by 20% and increase in revenue from the recently acquired multi-national Taro Pharmaceuticals by 21% over Q4FY10.

Higher top line, increase in other income by 1,094% and lower increase in material consumption saw operating profit rise by 36% to Rs 5.54 bn in Q4FY11. Increase in operation profit boosted bottom line by 29% y-o-y to Rs 5.03 bn.


## Revenue and EBITDA margins




## PAT and PAT margins



## Share price movement



## Shareholding pattern



## Additional Disclosure

This report has been sponsored by NSE - Investor Protection Fund Trust (NSEIPFT).

## Disclaimer

This report is based on data publicly available or from sources considered reliable. CRISIL Ltd. (CRISIL) does not represent that it is accurate or complete and hence, it should not be relied upon as such. The data / report is subject to change without any prior notice. Opinions expressed herein are our current opinions as on the date of this report. Nothing in this report constitutes investment, legal, accounting or tax advice or any solicitation, whatsoever. The subscriber / user assume the entire risk of any use made of this data / report. CRISIL especially states that, it has no financial liability whatsoever, to the subscribers / users of this report. This report is for the personal information only of the authorised recipient in India only. This report should not be reproduced or redistributed or communicated directly or indirectly in any form to any other person – especially outside India or published or copied in whole or in part, for any purpose.

CRISIL is not responsible for any errors and especially states that it has no financial liability whatsoever to the subscribers / users / transmitters / distributors of this report. For information please contact 'Client Servicing' at +91-22-33423561, or via e-mail: clientservicing@crisil.com.